RDNT vs. FLGT, BDSX, GTH, LH, DGX, NTRA, EXAS, GH, FTRE, and VCYT
Should you be buying RadNet stock or one of its competitors? The main competitors of RadNet include Fulgent Genetics (FLGT), Biodesix (BDSX), Genetron (GTH), Laboratory Co. of America (LH), Quest Diagnostics (DGX), Natera (NTRA), Exact Sciences (EXAS), Guardant Health (GH), Fortrea (FTRE), and Veracyte (VCYT). These companies are all part of the "medical" sector.
Fulgent Genetics (NASDAQ:FLGT) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership.
RadNet has a net margin of 1.28% compared to RadNet's net margin of -57.72%. Fulgent Genetics' return on equity of 5.05% beat RadNet's return on equity.
In the previous week, RadNet had 4 more articles in the media than Fulgent Genetics. MarketBeat recorded 6 mentions for RadNet and 2 mentions for Fulgent Genetics. RadNet's average media sentiment score of 1.86 beat Fulgent Genetics' score of 1.12 indicating that Fulgent Genetics is being referred to more favorably in the media.
Fulgent Genetics has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, RadNet has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.
RadNet has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.
RadNet received 97 more outperform votes than Fulgent Genetics when rated by MarketBeat users. Likewise, 65.70% of users gave RadNet an outperform vote while only 60.70% of users gave Fulgent Genetics an outperform vote.
48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 31.8% of Fulgent Genetics shares are held by company insiders. Comparatively, 5.1% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Fulgent Genetics currently has a consensus price target of $30.00, indicating a potential upside of 45.28%. RadNet has a consensus price target of $57.25, indicating a potential downside of 2.37%. Given RadNet's higher possible upside, equities analysts clearly believe Fulgent Genetics is more favorable than RadNet.
Summary
RadNet beats Fulgent Genetics on 15 of the 18 factors compared between the two stocks.
Get RadNet News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
